Literature DB >> 14280256

STEROID THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON IMMUNOLOGIC CONSIDERATIONS.

K LANGE, R ORES, W STRAUSS, M WACHSTEIN.   

Abstract

Entities:  

Keywords:  BIOPSY; BLOOD UREA NITROGEN; CALCINOSIS; COMPLEMENT; DRUG THERAPY; GAMMA GLOBULIN; IMMUNOLOGY; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; PREDNISONE, THERAPEUTIC; PROTEINURIA; PSYCHOSES; TOXICOLOGIC REPORT; TRIAMCINOLONE; TUBERCULOSIS, PULMONARY

Mesh：

Substances：

Year:  1965        PMID： 14280256     DOI： 10.1002/art.1780080208

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  8 in total

Review 1.  Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

Authors:  P E Spronk; H Bootsma; C G Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Immunosuppressive drugs in the management of malignant and severe rheumatoid arthritis.

Authors:  M F Kahn; M Bedoiseau; S de Sèze
Journal:  Proc R Soc Med       Date:  1967-02

3.  Acute renal failure in systemic lupus erythematosus.

Authors:  C Ponticelli; E Imbasciati; D Brancaccio; A Tarantino; E Rivolta
Journal:  Br Med J       Date:  1974-09-21

4.  [Clinical findings and prognosis of kidney manifestations in systemic lupus erythematosus].

Authors:  W Hartl; R Roos; E Genth
Journal:  Klin Wochenschr       Date:  1970-06-15

Review 5.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 6.  Antinuclear antibodies and nuclear antigens.

Authors:  E V Barnett
Journal:  Calif Med       Date:  1966-06

7.  Plasma C3 and C4 concentrations in management of glomerulonephritis.

Authors:  J S Cameron; R M Vick; C S Ogg; W M Seymour; C Chantler; D R Turner
Journal:  Br Med J       Date:  1973-09-29

Review 8.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.